MedTrace Logo

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

NCT05839301 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2023-06-18

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

Conditions

  • Varicella

Interventions

BIOLOGICAL

Investigational live attenuated varicella vaccine (lot 1)

0.5ml/vial

BIOLOGICAL

Investigational live attenuated varicella vaccine (lot 2)

0.5ml/vial

BIOLOGICAL

Investigational live attenuated varicella vaccine (lot 3)

0.5ml/vial

Sponsors & Collaborators

  • Beijing Institute of Biological Products Co Ltd.

    collaborator INDUSTRY

  • Jiangsu Province Center for Disease Control and Prevention

    collaborator UNKNOWN

  • China National Biotec Group Company Limited

    lead INDUSTRY

Principal Investigators

  • Hongxing Pan · Jiangsu Province Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2023-07-30
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05839301 on ClinicalTrials.gov